In a groundbreaking discovery, scientists have identified an enzyme that could enhance the effectiveness and longevity of popular medications such as Ozempic and Wegovy, potentially revolutionizing treatments for diabetes and weight loss.
The enzyme, known as PapB, employs a technique called macrocyclization to form peptide drugs into compact ring shapes. This process increases their durability and resistance to degradation within the body, as detailed by researchers from the University of Utah in their study published in ACS Publications.
Peptides are known for their potency, and when configured into rings, they gain significant benefits. These ring structures bolster the stability of the drugs, prolong their active lifespan in the body, and improve their interaction with biological targets, as explained by co-author Karsten Eastman.
This advancement translates to medications with more potent and prolonged effects, according to the researchers.
“The GLP-1 backbones developed by big pharmaceutical companies are already outstanding,” Eastman noted. “Our contribution is an efficient, late-stage enzymatic enhancement that can amplify the performance of these molecules.”
The potential applications of this discovery extend beyond just Ozempic. Researchers are optimistic about the implications for other peptide-based treatments targeting gastrointestinal issues and cancerous tumors.
Ozempic and Wegovy are injectable drugs that mimic a natural hormone to suppress appetite, slow digestion and lower blood sugar — helping patients manage Type 2 diabetes or lose significant weight, respectively.
